Melanoma Institute Australia

Pathological assessment of neoadjuvant‐treated melanoma specimens: a historical overview, lessons learned along the way and the road ahead

Neoadjuvant therapy has been recently established as the standard of care in surgically resectable stage III melanoma. Insofar as the extent of tumour response correlates with metrics of patient survival, this underscores the critical ongoing need for rigorous and reproducible ap...

Evaluating the use, acceptability, usability, and perceptions of melanoma risk prediction tools for estimating melanoma risk among the community and patients in Australia: a mixed methods study

Abstract Background To identify high-risk individuals, melanoma risk prediction tools have been developed. However, little is known about their use in practice by patients and the community. We assessed the use, usability and acceptability of two validated melanoma risk predictio...

A serum protein–to–bilirubin ratio predicts immune-mediated hepatotoxicity in lung cancer patients treated with immune-checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) have transformed outcomes for patients with advanced non-small cell lung cancer (NSCLC) but are associated with immune-related adverse events, including hepatotoxicity. Immune-mediated liver injury can necessitate treatment interruption and imm...